Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Psychiatric Quarterly
Published in: Psychiatric Quarterly 2/2008

01-06-2008 | Original Paper

Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice

Authors: Douglas L. Boggs, Deanna L. Kelly, Raymond C. Love, Robert P. McMahon, Robert R. Conley

Published in: Psychiatric Quarterly | Issue 2/2008

Login to get access

Abstract

Objective

This study compares patient characteristics and treatment response between inpatients treated with clozapine in a research setting as compared to those initiated on clozapine during routine inpatient treatment.

Methods

Subjects on clozapine, in clinical trials, were compared with clozapine inpatients receiving routine clinical care.

Results

At baseline, patients in routine clinical practice had more negative symptoms (P < 0.001), activation (P < 0.001) and greater total Brief Psychiatric Rating Scale (BPRS) scores (P = 0.022) than those in the research setting. Routine clinical practice subjects had larger decreases in BPRS total scores (P = 0.042) and positive item scores (P = 0.0005) compared to research subjects. Response to clozapine was observed in 15/85 (18%) research subjects as compared to 60/223 (27%) patients in routine care (P = 0.09).

Conclusions

Patients treated in routine clinical practice have more severe baseline symptoms, but experience significantly greater improvements in psychiatric symptoms.
Literature
1.
Clinical development of atypical antipsychotics: Research design and evaluation. Collaborative working group on clinical trial evaluations. The Journal of Clinical Psychiatry 59 Suppl 12:10–16, 1998
2.
Hofer A, Hummer M, Huber R, et al.: Selection bias in clinical trials with antipsychotics. Journal of clinical psychopharmacology 20(6):699–702, 2000PubMedCrossRef
3.
Licht RW, Gouliaev G, Vestergaard P, et al.: Generalisability of results from randomised drug trials. A trial on antimanic treatment. British Journal of Psychiatry 170:264–267, 1997PubMedCrossRef
4.
Robinson D, Woerner MG, Pollack S, et al.: Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study. Journal of clinical psychopharmacology 16(2):170–176, 1996PubMedCrossRef
5.
Spohn HE, Fitzpatrick T: Informed consent and bias in samples of schizophrenic subjects at risk for drug withdrawal. Journal of abnormal psychology 89(1):79–92, 1980PubMedCrossRef
6.
Woods SW, Ziedonis DM, Sernyak MJ, et al.: Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatric services 51(1):79–84, 2000PubMed
7.
Leber PD, Davis CS: Threats to the validity of clinical trials employing enrichment strategies for sample selection. Controlled Clinical Trials 19(2):178–187, 1998PubMedCrossRef
8.
Patten SB: Selection bias in studies of major depression using clinical subjects. Journal of Clininical Epidemiology 53(4):351–357, 2000CrossRef
9.
Breier A, Buchanan RW, Kirkpatrick B, et al.: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. American Journal of Psychiatry 151(1):20–26, 1994PubMed
10.
Chakos M, Lieberman J, Hoffman E, et al.: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158(4):518–526, 2001PubMedCrossRef
11.
Conley RR, Tamminga CA, Kelly DL, et al.: Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry 46(1):73–77, 1999PubMedCrossRef
12.
Azorin JM, Spiegel R, Remington G, et al.: A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. American Journal of Psychiatry 158(8):1305–1313, 2001PubMedCrossRef
13.
Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biological Psychiatry 50(11):898–911, 2001PubMedCrossRef
14.
Lehman AF, Lieberman JA, Dixon LB, et al.: Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161(2 Suppl):1–56, 2004PubMed
15.
Lehman AF, Kreyenbuhl J, Buchanan RW, et al.: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 30(2):193–217, 2004PubMed
16.
Miller AL, Hall CS, Buchanan RW, et al.: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. The Journal of Clinical Psychiatry 65(4):500–508, 2004PubMedCrossRef
17.
Stroup TS, McEvoy JP, Swartz MS, et al.: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29(1):15–31, 2003PubMed
18.
Brambilla P, Barale F, Caverzasi E, et al.: Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. International Clinical Psychopharmacology 17(4):189–195, 2002PubMedCrossRef
19.
Guy W: ECDEU assessment manual for psychopharmacology, revised (DHEW Publication No. ADM 76–338). Rockville, MD, US Department of Health and Human Services, 1976
20.
Slade E, Salkever D: Symptom effects on employment in a structural model of mental illness and treatment: analysis of patients with schizophrenia. The Journal of Mental Health Policy and Economics 4(1):25–34, 2001PubMed
21.
Hamilton NG, Ponzoha CA, Cutler DL, et al.: Social networks and negative versus positive symptoms of schizophrenia. Schizophrenia Bulletin 15(4):625–633, 1989PubMed
22.
Lysaker P, Bell M: Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatrica Scandinavica 91(3):205–208, 1995PubMedCrossRef
23.
Kane J, Honigfeld G, Singer J, et al.: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 45(9):789–796, 1988PubMed
24.
Krakowski MI, Czobor P, Citrome L, et al.: Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 63(6):622–629, 2006PubMedCrossRef
25.
Meltzer HY, Bastani B, Kwon KY, et al.: A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 99 Suppl:S68–S72, 1989CrossRef
26.
Rosenheck R, Lawson W, Crayton J, et al.: Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 44(6):475, 1998PubMedCrossRef
27.
Umbricht DS, Wirshing WC, Wirshing DA, et al.: Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. The Journal of Clinical Psychiatry 63(5):420–424, 2002PubMed
28.
Honer WG, Thornton AE, Chen EY, et al.: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. The New England Journal of Medicine 354(5):472–482, 2006PubMedCrossRef
29.
Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al.: A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. The Journal of Clinical Psychiatry 66(1):63–72, 2005PubMedCrossRef
30.
Lieberman JA, Safferman AZ, Pollack S, et al.: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry 151(12):1744–1752, 1994PubMed
31.
Pickar D, Owen RR Jr, Litman RE, et al.: Predictors of clozapine response in schizophrenia. The Journal of Clinical Psychiatry 55 Suppl B:129–132, 1994PubMed
32.
Buchanan RW, Breier A, Kirkpatrick B, et al.: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. American Journal of Psychiatry 155(6):751–760, 1998PubMed
33.
Iqbal MM, Rahman A, Husain Z, et al.: Clozapine: a clinical review of adverse effects and management. Annals of Clinical Psychiatry 15(1):33–48, 2003PubMedCrossRef
Metadata
Title
Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice
Authors
Douglas L. Boggs
Deanna L. Kelly
Raymond C. Love
Robert P. McMahon
Robert R. Conley
Publication date
01-06-2008
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 2/2008
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-008-9067-1

Other articles of this Issue 2/2008

Psychiatric Quarterly 2/2008 Go to the issue

Original Paper

Both Atomoxetine and Stimulants Improve Quality of Life in an ADHD Population Treated in a Community Clinic

Original Research

Professionals’ Attitudes Toward Reducing Restraint: The Case of Seclusion in The Netherlands

Original Paper

Examining Harry Thaw’s “Brain-Storm” Defense: APA and ANA Presidents as Expert Witnesses in a 1907 Trial

Original Paper

Comorbid Anxiety in Bipolar Disorder Alters Treatment and Prognosis

Erratum

The Use of Data to Assist in the Design of a New Service System for Homeless Veterans in New York City

Original Paper

Efficacy of Couple Therapy as a Treatment for Depression: A Meta-Analysis